3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
3
Breast
3
Gastrointestinal
2
Classical hematology
2
Sarcoma
1
Head & Neck
1
Gynecologic
1
Conditions
Sarcoma
195
Osteosarcoma
74
Sarcoma, Ewing
50
Rhabdomyosarcoma
50
Melanoma
43
Neuroblastoma
38
Neoplasms
33
Gastrointestinal Stromal Tumors
33
Neoplasm Metastasis
31
Colorectal Neoplasms
29
Glioblastoma
28
Bone Neoplasms
28
Breast Neoplasms
25
Glioma
24
Wilms Tumor
23
Rhabdoid Tumor
23
Carcinoma, Non-Small-Cell Lung
23
Ovarian Neoplasms
22
Gliosarcoma
22
Liposarcoma
21
Carcinoma, Renal Cell
20
Neurofibrosarcoma
19
Medulloblastoma
19
Lymphoma, Non-Hodgkin
19
Hepatoblastoma
19
Pancreatic Neoplasms
18
Desmoid Tumors
18
Thyroid Neoplasms
17
Sarcoma, Kaposi
17
Lymphoma
16
Interventions
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
sarilumab
1
pexidartinib
1
pertuzumab
1
pembrolizumab
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
durvalumab
1
dostarlimab
1
cemiplimab
1
abemaciclib
1
Trastuzumab
1
Standard of Care
1
STA 9090
1
SGN-LIV1A
1
Paclitaxel
1
MK 2206
1
Letrozole
1
Lasofoxifene
1
Irinotecan
1
Doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Sarcoma
×
90 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled